CD274 and extranodal nasal NK/T cell lymphoma: In addition, a PD-L1 mutation and a diverse baseline T cell receptor (TCR) repertoire have been proved a potential biomarkers to better select patients with NKTCL for anti-PD-1 therapy51,52.